Trinity Biotech (TRIB) Current Leases (2016 - 2025)

Trinity Biotech has disclosed Current Leases across 10 years of filings, most recently posting $2.6 million for Q4 2025.

• Current Leases for Q4 2025 came in at $2.6 million, up 13.26% year-over-year; the trailing twelve-month figure through Dec 2025 was $2.6 million (up 13.26% YoY), and the FY2025 annual result was $2.6 million, up 13.26% from the prior year.
• Current Leases came in at $2.6 million for Q4 2025 at Trinity Biotech, up from $2.3 million in the prior quarter.
• In the past five years, Current Leases ranged from a high of $2.6 million in Q4 2025 to a low of $1.7 million in Q4 2022.
• The 5-year median for Current Leases is $2.0 million (2021), against an average of $2.0 million.
• Across the five-year window, Current Leases fell 15.35% in 2022 and jumped 34.89% in 2024, its largest moves.
• Trinity Biotech's Current Leases stood at $2.0 million in 2021, then dropped by 15.35% to $1.7 million in 2022, then increased by 1.07% to $1.7 million in 2023, then jumped by 34.89% to $2.3 million in 2024, then gained by 13.26% to $2.6 million in 2025.
• The last three Current Leases figures came in at $2.6 million (Q4 2025), $2.3 million (Q4 2024), and $1.7 million (Q4 2023), per Business Quant data.